Topical corticosteroid preparations available in Australia
Drug (brand examples) |
Strength |
Preparations |
---|---|---|
Mild corticosteroids [NB1] [NB2] | ||
desonide (Desowen) |
0.05% |
lotion |
hydrocortisone (DermAid) hydrocortisone acetate (Cortic-DS, HydroCortic, Hysoderm, Sigmacort) |
0.5%, 1% |
cream, ointment, topical liquid, spray |
Moderate corticosteroids [NB1] [NB2] | ||
betamethasone valerate (Antroquoril, Betnovate 1/5, Celestone-M, Cortival 1/5) |
0.02% |
cream |
betamethasone valerate (Betnovate 1/2, Cortival 1/2) |
0.05% |
cream, ointment |
clobetasone butyrate (Eumovate, Kloxema) |
0.05% |
cream |
triamcinolone acetonide (Aristocort, Tricortone) |
0.02% |
cream, ointment |
Potent corticosteroids [NB1] [NB2] | ||
betamethasone dipropionate (Diprosone, Eleuphrat) |
0.05% |
cream, ointment, lotion |
betamethasone valerate (Betnovate) |
0.1% |
cream, ointment |
methylprednisolone aceponate (Advantan) [NB1] |
0.1% |
cream, ointment, fatty ointment, lotion |
mometasone furoate (Elocon, Momasone, Novasone, Zatamil) |
0.1% |
cream, ointment, hydrogel, lotion |
Very potent corticosteroids [NB1] [NB2] | ||
betamethasone dipropionate (Diprosone OV) |
0.05% in optimised vehicle |
ointment in optimised vehicle |
clobetasol propionate (Clobex) |
0.05% |
cream, ointment, lotion, shampoo [NB3] |
Note:
OV = optimised vehicle NB1: Potency classification for each drug is primarily based on the results of vasoconstrictor studies. Potency classifications based on vasoconstrictor effect typically correlate with therapeutic potency; however, many other factors determine therapeutic potency in a patient (eg area of application, frequency and duration of treatment)Ference, 2009. Potency classifications of topical corticosteroids may differ depending on the guideline or resource consulted; for example, although methylprednisolone aceponate is classed as 'moderate' in some references, it is the consensus of the Dermatology Expert Group that methylprednisolone aceponate is more potent than other topical corticosteroids listed in the 'moderate' category. NB2: Formulation of a drug can affect potency; a topical drug prepared as a cream is less potent than the same drug prepared as an ointment. See also formulation considerations when choosing a topical corticosteroid. NB3: A commercial product is available for clobetasol propionate as a shampoo. Clobetasol propionate as a cream, ointment or lotion is not registered for use in Australia, but is available through the Special Access Scheme (for certain indications) or from compounding pharmacies; only use these under specialist supervision. |